Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.63 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.62 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.62 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.62 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 4/20 | 0.58 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.56 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9043616 | 0.85 | MAOB (0.67) | MAOBNR4A1NR4A2NR4A3PARP10 | |
| SCHEMBL8354367 | 0.85 | MAOB (0.66) | MAOBNR4A2SRD5A2 | |
| SCHEMBL27875463 | 0.84 | NR4A1 (0.70) | MAOBNR4A1NR4A2NR4A3PARP10 | |
| SCHEMBL5386288 | 0.84 | NR4A1 (0.68) | MAOBNR4A1NR4A2NR4A3PARP10 | |
| SCHEMBL978502 | 0.81 | RAB9A (0.71) | MAOBNR4A1NR4A2NR4A3PARP10 | |
| SCHEMBL15596323 | 0.81 | MAOB (0.66) | MAOBNR4A1NR4A2NR4A3PARP10 | |
| SCHEMBL8208242 | 0.81 | ALOX5 (0.59) | MAOBNR4A1NR4A2NR4A3EGFR | |
| SCHEMBL10497637 | 0.81 | MAOB (0.61) | MAOBNR4A1NR4A2NR4A3PARP10 | |
| SCHEMBL9199941 | 0.81 | MAOB (0.67) | MAOBSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL1080750 | 0.81 | NR4A1 (0.56) | MAOBNR4A1NR4A2NR4A3PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4486444-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | F. Hoffmann-La Roche AG (CH) | 2025-01-08 | — | — | EP | disclosed |
| CN-118871422-A | 3-Alkynyl carboxamides as AEP modulators | 豪夫迈·罗氏有限公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-2023165943-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023165943-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-09-07 | — | — | WO | disclosed |
| US-10647675-B2 | Biaryl derivative and medicine containing same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2020-05-12 | — | — | US | disclosed |
| US-20190055199-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2019-02-21 | — | — | US | disclosed |
| EP-3351533-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 2018-07-25 | — | — | EP | disclosed |
| US-20150183722-A1 | Process for the Preparation of O-Desmethyl Venlafaxine and Intermediate for Use Therein | CIPLA LIMITED (IN) | 2015-07-02 | — | — | US | disclosed |
| US-9012689-B2 | Process for the preparation of O-desmethyl venlafaxine and intermediate for use therein | CIPLA LIMITED (IN) | 2015-04-21 | — | — | US | disclosed |
| US-20120157544-A1 | Process for the Preparation of O-Desmethyl Venlafaxine and Intermediate for Use Therein | CIPLA LIMITED (IN) | 2012-06-21 | — | — | US | disclosed |
| EP-2454228-A2 | PROCESS FOR THE PREPARATION OF O-DESMETHYL VENLAFAXINE AND INTERMEDIATE FOR USE THEREIN | CIPLA LIMITED (IN) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011007136-A2 | PROCESS FOR THE PREPARATION OF O-DESMETHYL VENLAFAXINE AND INTERMEDIATE FOR USE THEREIN | CIPLA LIMITED (IN) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183722-A1 | Process for the Preparation of O-Desmethyl Venlafaxine and Intermediate for Use Therein | SLC6A2, SLC6A3, MAOA | MAOB 22/4885NR4A1 2307/4885NR4A2 3110/4885 |
| US-10647675-B2 | Biaryl derivative and medicine containing same | MAN2B1, CBR3, MANBA | MAOB 256/4885NR4A1 87/4885NR4A2 123/4885 |
| US-20190055199-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | MAN2B1, CBR3, MANBA | MAOB 256/4885NR4A1 87/4885NR4A2 123/4885 |
| US-20120157544-A1 | Process for the Preparation of O-Desmethyl Venlafaxine and Intermediate for Use Therein | SLC6A2, SLC6A3, MAOA | MAOB 22/4885NR4A1 2307/4885NR4A2 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.